1. The role of TNF-α in chordoma progression and inflammatory pathways.
- Author
-
Gulluoglu S, Tuysuz EC, Sahin M, Yaltirik CK, Kuskucu A, Ozkan F, Dalan AB, Sahin F, Ture U, and Bayrak OF
- Subjects
- ATP Binding Cassette Transporter, Subfamily G, Member 2 metabolism, Adult, Aged, B7-H1 Antigen metabolism, Biomarkers, Tumor metabolism, Bone Neoplasms drug therapy, Bone Neoplasms mortality, Cell Line, Tumor, Cell Movement drug effects, Child, Chordoma drug therapy, Chordoma mortality, Chordoma secondary, Disease Progression, Drug Resistance, Neoplasm, Female, Humans, Inflammation, Leukemia Inhibitory Factor metabolism, Lymphocytes metabolism, Male, Middle Aged, Neoplasm Proteins metabolism, Neutrophils metabolism, Prognosis, Receptors, Tumor Necrosis Factor, Type I metabolism, Retrospective Studies, Signal Transduction drug effects, Tumor Necrosis Factor-alpha metabolism, Tumor Necrosis Factor-alpha pharmacology, Young Adult, Bone Neoplasms pathology, Chordoma pathology, Epithelial-Mesenchymal Transition drug effects, Tumor Necrosis Factor-alpha physiology
- Abstract
Purpose: Chordomas are highly therapy-resistant primary bone tumors that exhibit high relapse rates and may induce local destruction. Here, we evaluated the effects of tumor necrosis factor-alpha (TNF-α) on chordoma progression and clinical outcome., Methods: Chordoma cells were treated with TNF-α after which its short- and long-term effects were evaluated. Functional assays, qRT-PCR and microarray-based expression analyses were carried out to assess the effect of TNF-α on chemo-resistance, epithelial to mesenchymal transition (EMT), migration, invasion and cancer stem cell-like properties. Finally, relationships between TNF-α expression and clinicopathological features were assessed in a chordoma patient cohort., Results: We found that TNF-α treatment increased the migration and invasion of chordoma cells. Also, NF-κB activation was observed along with increased EMT marker expression. In addition, enhanced tumor sphere formation and soft agar colony formation were observed, concomitantly with increased chemo-resistance and CD338 marker expression. The TNF-α and TNFR1 expression levels were found to be significantly correlated with LIF, PD-L1 and Ki67 expression levels, tumor volume and a short survival time in patients. In addition, a high neutrophil to lymphocyte ratio was found to be associated with recurrence and a decreased overall survival., Conclusions: From our data we conclude that TNF-α may serve as a prognostic marker for chordoma progression and that tumor-promoting inflammation may be a major factor in chordoma tumor progression.
- Published
- 2019
- Full Text
- View/download PDF